Table 10.

Lists the two RCTs identified with RLS and BoNT.

Study	Study Design	Method	Results
Mittal, 2018 [275]	Double-blinded, placebo-controlled crossover randomized controlled trial (RCT) Formulation used: incobotulinumtoxinA	Sample size (N): 24 40 units each for tibialis anterior (TA), gastrocnemius (GCS) and 20 units in biceps femoris bilaterally Controls were injected with saline	International restless legs syndrome score improved at Week 4 (p = 0.0036) and Week 6 (p = 0.0325). No significant improvement at Week 8 (p = 0.067) They concluded that incobotulinumtoxinA injected improved RLS severity without adverse events
Nahab, 2008 [279]	Double-blinded, placebo-controlled crossover RCT Formulation used: onabotulinumtoxinA	n = 6 40 mU Quadriceps femoris (QF), 20 mU TA, 20 mU GCS, and 10 mU soleus (SOL) under EMG guidance Max dose: 90 mU/leg Controls were injected with saline	A statistically significant benefit was not noted, and adverse effects were similar with both groups

Abbreviations: EMG—Electromyography; GCS—Gastrocnemius; QF—Quadriceps femoris; RLS—Restless leg syndrome; RCT—Randomized controlled trial; SO—Soleus; TA—Tibialis anterior.